Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2011-06-14
2011-06-14
Jarrell, Noble (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S462000, C546S018000, C549S466000, C549S468000
Reexamination Certificate
active
07960402
ABSTRACT:
A compound represented by, e.g. the formula (I):[wherein X, Y, Z, and W each independently represent optionally substituted methine; A, B, and D each independently represent —C(O)—, etc.; Q represents a methine or a nitrogen; and R represents the formula (II-1), optionally substituted with lower alkyl, etc.;(wherein R6represents a lower alkyl, etc; and R7and R8each independently represents a lower alkyl, etc.)] or a pharmaceutically acceptable salt of the compound. The compounds and salt have antagonistic activity against a histamine H3 receptor or inverse agonistic activity against a histamine H3 receptor. They are useful in the prevention or treatment of metabolic diseases, circulatory diseases, or neurotic diseases.
REFERENCES:
patent: 6191160 (2001-02-01), Gao et al.
patent: 6313298 (2001-11-01), Gao et al.
patent: 6326375 (2001-12-01), Fukami et al.
patent: 6335345 (2002-01-01), Fukami et al.
patent: 6388077 (2002-05-01), Fukami et al.
patent: 6462053 (2002-10-01), Fukami et al.
patent: 6495559 (2002-12-01), Gao et al.
patent: 6638942 (2003-10-01), Gao et al.
patent: 6649624 (2003-11-01), Fukami et al.
patent: 6723847 (2004-04-01), Fukami et al.
patent: 6803372 (2004-10-01), Fukami et al.
patent: 7365079 (2008-04-01), Otake et al.
patent: 7589096 (2009-09-01), Otake et al.
patent: 2002/0052371 (2002-05-01), Fukami et al.
patent: 2002/0058813 (2002-05-01), Gao et al.
patent: 2002/0165391 (2002-11-01), Fukami et al.
patent: 2002/0188124 (2002-12-01), Fukami et al.
patent: 2003/0055251 (2003-04-01), Fukami et al.
patent: 2003/0220499 (2003-11-01), Fukami et al.
patent: 2004/0063942 (2004-04-01), Gao et al.
patent: 2005/0026901 (2005-02-01), Janssens et al.
patent: 2006/0111380 (2006-05-01), Otake et al.
patent: 2008/0188507 (2008-08-01), Otake et al.
patent: 2009/0258871 (2009-10-01), Jitsuoka et al.
patent: 1795527 (2005-09-01), None
Witjmans et al. Expert Opinion on Investigational Drugs, 2007, 16(7), 967-985.
Bergquist et al. Acta Physiologica Sinica, 2006, 58(4), 293-304.
“Association of Clinical Research Professionals—Clinical Trial Updates”, http://www.acrpnet.org/MainMenuCategory/Resources/TheWire/ClinicalTrialUpdates.aspx, accessed Jun. 18, 2010.
Lintunen et al. The FASEB Journal, 2001, pp. 1-20.
Zarrindast et al. Pharmacology and Toxicology, 2000, 87, pp. 169-173.
“Type II diabetes”, http://diabetes.webmd.com/type-2-diabetes, accessed Jun. 18, 2010.
Leopold. Chemical Senses, 2002, 27, pp. 611-615.
Hancoock et al. Expert Opinion on Investigational Drugs, 2004, 13(10), 1237-48.
Zheng et al. Pharmacological Reviews, 2006, 58(2), 259-79.
Supplementary European Search Report for EP 05 77 8590, Jan. 8, 2008.
Jitsuoka Makoto
Ohtake Norikazu
Sato Nagaaki
Tokita Shigeru
Tsukahara Daisuke
Banyu Pharmaceutical Co. Ltd.
Devlin Gerard M.
Jarrell Noble
Thies J. Eric
LandOfFree
Carbamoyl-substituted spiro derivative does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Carbamoyl-substituted spiro derivative, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Carbamoyl-substituted spiro derivative will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2652244